SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data

SAB Biotherapeutics ( (SABS) ) has provided an update.

On March 10, 2026, SAB Biotherapeutics, Inc. reported additional Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established autoimmune type 1 diabetes. The company simultaneously made a detailed data presentation and an expert webinar by T1D key opinion leader Michael J. Haller available to clinicians and investors.

In the Phase 1 HUMAN trial’s established T1D cohort of six adults, four patients who received SAB-142 at 2.5 mg/kg showed preserved, and on average slightly increased, C-peptide levels at Day 120 versus baseline, while the placebo participant who completed follow-up showed a decline consistent with expected disease progression. These exploratory signals, supported by biomarker evidence of T cell exhaustion, build on earlier safety and pharmacodynamic results and underpin SAB BIO’s decision to advance SAB-142 into the ongoing registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D across adults, adolescents, and children.

By diverging from both the study placebo subject and a modeled historical placebo cohort from the TN19 trial, SAB-142’s early pharmacodynamic profile suggests potential preservation of beta cell function in established T1D. For stakeholders, the data offer incremental clinical validation of SAB-142’s mechanism and reinforce SAB BIO’s positioning as a contender in disease-modifying therapies for type 1 diabetes, while the active global enrollment in SAFEGUARD signals a clear path toward later-stage efficacy readouts.

The most recent analyst rating on (SABS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

Spark’s Take on SABS Stock

According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.

The score is held back primarily by weak financial performance (sharp revenue contraction, negative gross profit, and sustained cash burn). Technicals are neutral-to-slightly constructive (above key longer-term moving averages with neutral momentum), while corporate updates provide some support but are tempered by dilution risk from the new ATM program; valuation is constrained by ongoing losses and no dividend.

To see Spark’s full report on SABS stock, click here.

More about SAB Biotherapeutics

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing multi-specific, fully human immunoglobulin G therapies for immune and autoimmune disorders, including type 1 diabetes. Using genetically engineered transchromosomic cattle to produce high-potency human antibodies, its lead candidate SAB-142 targets autoimmune type 1 diabetes with a disease-modifying approach, and is currently in a registrational Phase 2b trial called SAFEGUARD.

Average Trading Volume: 356,087

Technical Sentiment Signal: Buy

Current Market Cap: $182.8M

For a thorough assessment of SABS stock, go to TipRanks’ Stock Analysis page.